These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 12356793

  • 21. Comparative in vitro potency of gemifloxacin against European respiratory tract pathogens isolated in the Alexander Project.
    Marchese A, Debbia EA, Schito GC.
    J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():11-5. PubMed ID: 10997594
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Comparative in vitro activity of older and newer fluoroquinolones against respiratory tract pathogens.
    Esposito S, Noviello S, Ianniello F.
    Chemotherapy; 2000 Jul; 46(5):309-14. PubMed ID: 10965095
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005.
    Sahm DF, Brown NP, Draghi DC, Evangelista AT, Yee YC, Thornsberry C.
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):8-15. PubMed ID: 18931466
    [Abstract] [Full Text] [Related]

  • 27. Pharmacodynamic characterization of efflux and topoisomerase IV-mediated fluoroquinolone resistance in Streptococcus pneumoniae.
    Madaras-Kelly KJ, Daniels C, Hegbloom M, Thompson M.
    J Antimicrob Chemother; 2002 Aug; 50(2):211-8. PubMed ID: 12161401
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. AWARE Ceftaroline Surveillance Program (2008-2010): trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States.
    Pfaller MA, Farrell DJ, Sader HS, Jones RN.
    Clin Infect Dis; 2012 Sep; 55 Suppl 3():S187-93. PubMed ID: 22903951
    [Abstract] [Full Text] [Related]

  • 32. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens.
    Rittenhouse S, McCloskey L, Broskey J, Niconovich N, Jakielaszek C, Poupard J, Coleman K.
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():23-7. PubMed ID: 10824028
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
    Yang Q, Xu Y, Chen M, Wang H, Sun H, Hu Y, Zhang R, Duan Q, Zhuo C, Cao B, Liu Y, Yu Y, Sun Z, Chu Y.
    Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
    [Abstract] [Full Text] [Related]

  • 35. Mutant selection window of four quinolone antibiotics against clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis.
    Nakai H, Sato T, Uno T, Furukawa E, Kawamura M, Takahashi H, Watanabe A, Fujimura S.
    J Infect Chemother; 2018 Feb; 24(2):83-87. PubMed ID: 29290527
    [Abstract] [Full Text] [Related]

  • 36. Susceptibility patterns of bacterial isolates from hospitalised patients with respiratory tract infections (MOXIAKTIV Study).
    Jacobs E, Dalhoff A, Korfmann G.
    Int J Antimicrob Agents; 2009 Jan; 33(1):52-7. PubMed ID: 18835763
    [Abstract] [Full Text] [Related]

  • 37. Pharmacodynamic activity of fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.
    Zhanel GG, Roberts D, Waltky A, Laing N, Nichol K, Smith H, Noreddin A, Bellyou T, Hoban DJ.
    J Antimicrob Chemother; 2002 May; 49(5):807-12. PubMed ID: 12003975
    [Abstract] [Full Text] [Related]

  • 38. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
    LaPlante KL, Rybak MJ, Tsuji B, Lodise TP, Kaatz GW.
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740
    [Abstract] [Full Text] [Related]

  • 39. Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory or otorhinological infections: comparison with the results obtained from organisms isolated about 10 years ago.
    Hasegawa M, Sato Y, Kanayama A, Matsuzaki K, Muraoka H, Amano A, Saika T, Kobayashi I.
    J Infect Chemother; 2006 Jun; 12(3):152-6. PubMed ID: 16826349
    [Abstract] [Full Text] [Related]

  • 40. [Resistance study of community respiratory pathogens isolated in China from 2005 to 2007].
    Sun HL, Yang QW, Xu YC, Wang H, Xie XL, Chen MJ, Zhang XZ, Liu Y, Ye HF, Sun ZY, Duan Q, Ni YX, Yu YS, Zhao WS, He L, Wang J, Ji P, Liu PP, Zhang LX.
    Zhonghua Yi Xue Za Zhi; 2009 Nov 17; 89(42):2983-7. PubMed ID: 20137709
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.